276 related articles for article (PubMed ID: 23028510)
1. Anti-cancer activity of a novel small molecule compound that simultaneously activates p53 and inhibits NF-κB signaling.
Hwang SG; Park J; Park JY; Park CH; Lee KH; Cho JW; Hwang JI; Seong JY
PLoS One; 2012; 7(9):e44259. PubMed ID: 23028510
[TBL] [Abstract][Full Text] [Related]
2. Double-edged swords as cancer therapeutics: novel, orally active, small molecules simultaneously inhibit p53-MDM2 interaction and the NF-κB pathway.
Zhuang C; Miao Z; Wu Y; Guo Z; Li J; Yao J; Xing C; Sheng C; Zhang W
J Med Chem; 2014 Feb; 57(3):567-77. PubMed ID: 24428757
[TBL] [Abstract][Full Text] [Related]
3. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
[TBL] [Abstract][Full Text] [Related]
4. Curaxins: anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT.
Gasparian AV; Burkhart CA; Purmal AA; Brodsky L; Pal M; Saranadasa M; Bosykh DA; Commane M; Guryanova OA; Pal S; Safina A; Sviridov S; Koman IE; Veith J; Komar AA; Gudkov AV; Gurova KV
Sci Transl Med; 2011 Aug; 3(95):95ra74. PubMed ID: 21832239
[TBL] [Abstract][Full Text] [Related]
5. Novel derivative of benzofuran induces cell death mostly by G2/M cell cycle arrest through p53-dependent pathway but partially by inhibition of NF-kappaB.
Manna SK; Bose JS; Gangan V; Raviprakash N; Navaneetha T; Raghavendra PB; Babajan B; Kumar CS; Jain SK
J Biol Chem; 2010 Jul; 285(29):22318-27. PubMed ID: 20472557
[TBL] [Abstract][Full Text] [Related]
6. Aurora-A promotes gefitinib resistance via a NF-κB signaling pathway in p53 knockdown lung cancer cells.
Wu CC; Yu CT; Chang GC; Lai JM; Hsu SL
Biochem Biophys Res Commun; 2011 Feb; 405(2):168-72. PubMed ID: 21216229
[TBL] [Abstract][Full Text] [Related]
7. Cross talk between stimulated NF-kappaB and the tumor suppressor p53.
Schneider G; Henrich A; Greiner G; Wolf V; Lovas A; Wieczorek M; Wagner T; Reichardt S; von Werder A; Schmid RM; Weih F; Heinzel T; Saur D; Krämer OH
Oncogene; 2010 May; 29(19):2795-806. PubMed ID: 20190799
[TBL] [Abstract][Full Text] [Related]
8. Long noncoding RNA MEG3 inhibits breast cancer growth via upregulating endoplasmic reticulum stress and activating NF-κB and p53.
Zhang Y; Wu J; Jing H; Huang G; Sun Z; Xu S
J Cell Biochem; 2019 Apr; 120(4):6789-6797. PubMed ID: 30556250
[TBL] [Abstract][Full Text] [Related]
9. Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo.
Tiedemann RE; Schmidt J; Keats JJ; Shi CX; Zhu YX; Palmer SE; Mao X; Schimmer AD; Stewart AK
Blood; 2009 Apr; 113(17):4027-37. PubMed ID: 19096011
[TBL] [Abstract][Full Text] [Related]
10. p53 gene expression and 2-methoxyestradiol treatment differentially induce nuclear factor kappa B activation in human lung cancer cells with different p53 phenotypes.
Rath PC; Mukhopadhyay T
DNA Cell Biol; 2009 Dec; 28(12):615-23. PubMed ID: 19715480
[TBL] [Abstract][Full Text] [Related]
11. The citrus flavonoid hesperidin induces p53 and inhibits NF-κB activation in order to trigger apoptosis in NALM-6 cells: involvement of PPARγ-dependent mechanism.
Ghorbani A; Nazari M; Jeddi-Tehrani M; Zand H
Eur J Nutr; 2012 Feb; 51(1):39-46. PubMed ID: 21445621
[TBL] [Abstract][Full Text] [Related]
12. Reciprocal inhibition of p53 and nuclear factor-kappaB transcriptional activities determines cell survival or death in neurons.
Culmsee C; Siewe J; Junker V; Retiounskaia M; Schwarz S; Camandola S; El-Metainy S; Behnke H; Mattson MP; Krieglstein J
J Neurosci; 2003 Sep; 23(24):8586-95. PubMed ID: 13679428
[TBL] [Abstract][Full Text] [Related]
13. RRAD, IL4I1, CDKN1A, and SERPINE1 genes are potentially co-regulated by NF-κB and p53 transcription factors in cells exposed to high doses of ionizing radiation.
Szołtysek K; Janus P; Zając G; Stokowy T; Walaszczyk A; Widłak W; Wojtaś B; Gielniewski B; Cockell S; Perkins ND; Kimmel M; Widlak P
BMC Genomics; 2018 Nov; 19(1):813. PubMed ID: 30419821
[TBL] [Abstract][Full Text] [Related]
14. Nitric Oxide-Releasing Aspirin Suppresses NF-κB Signaling in Estrogen Receptor Negative Breast Cancer Cells in Vitro and in Vivo.
Nath N; Chattopadhyay M; Rodes DB; Nazarenko A; Kodela R; Kashfi K
Molecules; 2015 Jul; 20(7):12481-99. PubMed ID: 26184135
[TBL] [Abstract][Full Text] [Related]
15. Attenuated transforming growth factor beta signaling promotes nuclear factor-kappaB activation in head and neck cancer.
Cohen J; Chen Z; Lu SL; Yang XP; Arun P; Ehsanian R; Brown MS; Lu H; Yan B; Diallo O; Wang XJ; Van Waes C
Cancer Res; 2009 Apr; 69(8):3415-24. PubMed ID: 19351843
[TBL] [Abstract][Full Text] [Related]
16. Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-кB target genes in human breast cancer.
Dalmases A; González I; Menendez S; Arpí O; Corominas JM; Servitja S; Tusquets I; Chamizo C; Rincón R; Espinosa L; Bigas A; Eroles P; Furriol J; Lluch A; Rovira A; Albanell J; Rojo F
Oncotarget; 2014 Jan; 5(1):196-210. PubMed ID: 24344116
[TBL] [Abstract][Full Text] [Related]
17. Asian ginseng extract inhibits in vitro and in vivo growth of mouse lewis lung carcinoma via modulation of ERK-p53 and NF-κB signaling.
Wong VK; Cheung SS; Li T; Jiang ZH; Wang JR; Dong H; Yi XQ; Zhou H; Liu L
J Cell Biochem; 2010 Nov; 111(4):899-910. PubMed ID: 20665661
[TBL] [Abstract][Full Text] [Related]
18. Synergistic growth inhibition of squamous cell carcinoma of the head and neck by erlotinib and epigallocatechin-3-gallate: the role of p53-dependent inhibition of nuclear factor-kappaB.
Amin AR; Khuri FR; Chen ZG; Shin DM
Cancer Prev Res (Phila); 2009 Jun; 2(6):538-45. PubMed ID: 19470788
[TBL] [Abstract][Full Text] [Related]
19. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors.
Gurova KV; Hill JE; Guo C; Prokvolit A; Burdelya LG; Samoylova E; Khodyakova AV; Ganapathi R; Ganapathi M; Tararova ND; Bosykh D; Lvovskiy D; Webb TR; Stark GR; Gudkov AV
Proc Natl Acad Sci U S A; 2005 Nov; 102(48):17448-53. PubMed ID: 16287968
[TBL] [Abstract][Full Text] [Related]
20. A novel drug discovery strategy: mechanistic investigation of an enantiomeric antitumor agent targeting dual p53 and NF-κB pathways.
Zhuang C; Sheng C; Shin WS; Wu Y; Li J; Yao J; Dong G; Zhang W; Sham YY; Miao Z; Zhang W
Oncotarget; 2014 Nov; 5(21):10830-9. PubMed ID: 25350970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
